Bafna Pharmaceuticals (BAFNAPH) Q1 25/26 earnings summary

Executive summary

• Unaudited financial results for the quarter ended June 30, 2025, were approved and reviewed by the Board and auditors, with the AGM scheduled for September 19, 2025.

• The company completed the sale of assets at the Madhavaram manufacturing unit during the quarter.

Financial highlights

• Revenue from operations for Q1 FY26 was ₹3,462.40 lakhs, up from ₹3,328.63 lakhs in Q1 FY25.

• Total income for the quarter was ₹3,521.96 lakhs, compared to ₹3,379.16 lakhs in the same quarter last year.

• Profit before tax was ₹338.89 lakhs, a turnaround from a loss of ₹72.36 lakhs in Q1 FY25.

• Earnings per share (basic and diluted) for the quarter stood at ₹1.43, compared to a loss of ₹0.31 in Q1 FY25.

Outlook and guidance

• The company is in the process of obtaining a waiver for penalties related to previous non-compliance with minimum public shareholding requirements.